Videos

Genomic Testing Practices in Prostate Cancer

David M. O’Malley, MD, spoke about the approval of pembrolizumab for patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Novel Approaches to Optimizing Management of mHSPC

Expert perspectives on optimal genomic testing practices in patients with prostate cancer.

Robert Dreicer, MD, MS, FACP;Saby George, MD;Mark Scholz, MD

Sam Klempner, MD, Talks ctDNA for Nonmetastatic Gastric and Esophageal Cancers

Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.

Sam Klempner, MD

Nina Shah, MD, Discusses Key Results of the Phase 2 KarMMa Trial of Ide-Cel in R/R Multiple Myeloma

Sam Klempner, MD, spoke about clinical management and ctDNA for gastrointestinal cancers.

Nina Shah, MD

Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?

At the 2022 Tandem Meetings, Nina Shah, MD, spoke about key findings from the phase 2 KarMMa trial that used idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

Robert J. Motzer, MD;David Aggen, MD, PhD;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Brian I. Rini, MD

Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC

Stefania Maraka, MD, explains the second- and third-line treatment options for metastatic HER2+ breast cancer and how she collaborates with breast oncologists.

Peter Humphrey MD, PhD

Daniel P. Petrylak, MD, Reviews Ongoing Clinical Trials in Bladder Cancer

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

Daniel P. Petrylak, MD

April 22nd 2022

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.

Ursula A. Matulonis, MD, on the Safety of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

Ursula A. Matulonis, MD

April 22nd 2022

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.

Frederick Locke, MD, Reviews the Next Steps for Axi-Cel in LBCL

Frederick Locke, MD

Unmet Needs and Future Perspectives in Multiple Myeloma Treatment

Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

Novel Agents Under Investigation for Multiple Myeloma

A look at the unmet needs and future directions of multiple myeloma treatment.

Rafael Fonseca, MD;Caitlin Costello, MD;Krina K. Patel, MD;Jeffrey V. Matous, MD;Robert Z. Orlowski, MD, PhD

JAVELIN Bladder 101: Study Design and Patient Outcomes

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

The Role of Biomarkers in Immunotherapy Selection for mUC

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma

Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Mehmet Asim Bilen, MD;Marie Carlo, MD;Robert J. Motzer, MD;Moshe Ornstein, MD, MA;Brian I. Rini, MD;Rana R. McKay, MD;Tom Powles, MBBS, MRCP, MD

The Role of Prophylaxis Regimens for GVHD

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Counseling Patients on the Long-Term Management of GVHD

Yi-Bin Chen, MD, reviews factors affecting treatment selection among available pharmacological and ex vivo prophylaxis approaches for GVHD.

John F. D. Dipersio, MD, PhD;Yi-Bin Chen, MD;Hannah Choe, MD;Pashna N. Munshi, MD

Susan F. Slovin, MD, PhD, Reviews Future Landscape of Systemic Therapies for Prostate Cancer

Thought leaders in stem cell transplant and cellular immunotherapy share insights into how they counsel patients about the challenges associated with the long-term management of chronic GVHD.

Susan F. Slovin, MD, PhD